INTRODUCTION
The IAP (inhibitor of apoptosis) proteins are a family of cell-death regulators found in viruses and metazoans. IAPs can interact directly with a variety of inducers and effectors of apoptosis, and can block apoptosis induced by diverse stimuli [1] [2] [3] . This places IAPs in a central position as inhibitors of death signals that proceed through a number of different pathways. The IAPs contain one to three zinc-binding BIR (baculovirus IAP repeat) domains that are required for anti-apoptotic activity [4, 5] . Most of them also possess C-terminal RING (really interesting new gene) domains that function as ubiquitin ligases [5, 6] . Some IAPs, such as c-IAP (cellular IAP) 1 and 2, possess a CARD (caspase activation and recruitment domain) as well [7] . c-IAP1 and c-IAP2 were originally identified through their ability to interact directly with TRAF2 [TNF (tumour necrosis factor)-associated factor 2] [8, 9] . Through TRAF2 interactions, c-IAP1 and c-IAP2 are recruited to TNFR (TNF receptor) 1-and 2-associated complexes, where they regulate receptor-mediated signalling [10, 11] . c-IAP1 and c-IAP2 are critical regulators of NF-κB (nuclear factor κB) signalling pathways [12] . In the TNFα-induced canonical NF-κB pathway, c-IAP1 and c-IAP2 are required for RIP1 (receptor-interacting protein 1) ubiquitination and NF-κB activation [13] [14] [15] . In the non-canonical NF-κB pathway, c-IAP1 and c-IAP2 ubiquitinate NIK (NF-κB-inducing kinase), leading to its proteasomal degradation and abrogation of NF-κB signalling [16] .
The regulated degradation and modification of cellular proteins by the ubiquitin-proteasome system affects a range of vital cellular processes in both normal and tumour cells [17] . An increasing body of work suggests that E3 ubiquitin ligase activity is an essential function of IAPs [6, 18] . IAPs are capable of promoting ubiquitination and subsequent proteasomal degradation of themselves and several of their binding partners, including TRAF2 and NIK [16, 19, 20] . A Drosophila IAP, DIAP1, inhibits cell death, at least in part, by mediating ubiquitination and proteasomal degradation of the Drosophila caspases and IAP antagonistic proteins Reaper, Hid and Grim [21, 22] . IAP antagonists promote auto-ubiquitination and proteasomal degradation of c-IAP1 and c-IAP2 in a process that is very efficient and extremely rapid [13, 16, 23] . Proteasome inhibitors can block the degradation induced by IAP antagonists, but questions still remain regarding the regulation of c-IAP1 and c-IAP2 proteasomal degradation.
In the present study, we have identified the existence of a UBA (ubiquitin-associated) domain in IAPs and characterized its biochemical properties. Our results show that the UBA domain of c-IAP1 binds both mono-ubiquitin and Lys 48 -and Lys 63 -linked polyubiquitin chains, with the highly conserved MGF (Met-GlyPhe) binding loop of the UBA domain playing a critical role in this interaction. The UBA domains of c-IAP1 and c-IAP2 are not critical for their engagement in TNF signalling complexes or for their E3 ubiquitin ligase activities. We demonstrate that the UBA domain plays an important role in IAP antagonist-stimulated proteasomal degradation of c-IAP1 and c-IAP2 by facilitating their recruitment to the proteasome.
EXPERIMENTAL

Plasmids, antibodies and immunoprecipitations
Plasmids expressing FLAG-c-IAP1, FLAG-c-IAP2, mutant FLAG-c-IAP1 and FLAG-c-IAP2 constructs that lack the ability to bind TRAF2 (T2bm), FLAG-c-IAP1 RING mutant (H588A), Smac (second mitochondrial-derived activator of caspase)-Myc, TRAF2-Myc, HA (haemagglutinin)-c-IAP2/MALT1 (mucosaassociated lymphoid tissue protein 1) (case2), and HA-case2 delBIR1 have been described previously [16, 24] . Deletions and point mutations of c-IAP1 and c-IAP2 were generated by PCR and subcloned into the p3XFLAG-CMV-14 vector (Sigma) or pEF6/V5-His vector (Invitrogen). Site-specific mutants in c-IAP1, c-IAP2 and case2 were generated using a QuikChange ® sitedirected mutagenesis kit (Stratagene). All constructs were verified by sequencing of the entire coding region. Human recombinant soluble TNFα was from Genentech. The primary antibodies against c-IAP1 were purchased from R&D Systems (affinity-purified goat antibody) or PTG; anti-ubiquitin antibody was from Cell Signaling Technology; anti-TRAF2 antibodies were from Santa Cruz Biotechnology; anti-TNFR1 antibodies were from R&D Systems; anti-TRADD (TNF-associated death domain) and anti-RIP1 antibodies were from BD Biosciences; anti-FLAG M2 antibody was from Sigma, anti-HA antibody was from Covance, anti-RPN13 (regulatory particle non-ATPase 13) antibody was from Biomol; anti-Myc antibody was from Roche; anti-β-tubulin antibody was from ICN Biomedicals. MG132 was purchased from Calbiochem, and IAP antagonist BV6 [16] was from Genentech. Western blot analyses and immunoprecipitations were performed as described previously [25] .
Cell lines, transfections, NF-κB activity assay and viability assays HEK (human embryonic kidney)-293T cells, A2058 melanoma cells and HT1080 human fibrosarcoma cells were obtained from A.T.C.C. (Manassas, VA, U.S.A.); KMS18 multiple myeloma cells were from the Japanese Collection of Research Bioresources (JCRB). All cell lines were grown in 50:50 Dulbecco's modified Eagle's and FK12 medium supplemented with 10 % FBS (fetal bovine serum), penicillin and streptomycin. HEK-293T, A2058 and HT1080 cells were transfected with FuGENE6 reagent (Roche). KMS18 cells were transfected by electroporation using Amaxa Nucleofactor technology (Lonza). HEK-293T cells were transfected with the indicated constructs, and NF-κB luciferase activity was measured using the dual-luciferase reporter assay (Promega) according to the manufacturer's instructions. Viability of KMS18 cells was measured using the CellTiter-Glo Luminescent Cell Viability Assay (Promega).
Recombinant protein production
Polyubiquitin chains were purchased from Boston Biochem. Mono-ubiquitin was bacterially expressed in a pET15b vector using either TB (tryptone broth) medium [enriched LB (LuriaBroth) medium] or minimal medium containing 15 NH 4 Cl and [
13 C]glucose to produce 13 C/ 15 N-isotopically labelled protein. The c-IAP1 UBA domain (residues 379-445), CARD (residues 454-542 or 454-550), BIR3-UBA domain (residues 241-445) and UBA domain-CARD (residues 379-550), as well as c-IAP2 UBA domain constructs (residues 365-431), were subcloned into either the pET15b or pET28a vectors and expressed in bacteria using LB, TB or 15 N-isotopically enriched minimal medium. Induction of protein expression was either carried out using manual induction with 1 mM IPTG (isopropyl β-D-thiogalactoside) or auto-induction using Overnight Express TM medium (Novagen). Purification of all expressed proteins used either a two-or three-step procedure, either affinity chromatography on Ni-NTA (Ni 2+ -nitrilotriacetate) resin (Qiagen) followed by size-exclusion chromatography (Superdex 75 16/60 or Superdex 200 16/60 columns; GE Healthcare) performed on anÄKTA Explorer FPLC machine, or affinity chromatography on Ni-NTA followed by thrombin cleavage of the His 6 affinity tag, dialysis and size-exclusion chromatography. PBS (pH 6.7-7.4), TBS (Trisbuffered saline; pH 7.2-7.4) and 20 mM Mes/150 mM NaCl (pH 6.0) were used as buffers. Full-length c-IAP1, c-IAP1 (M402A/F404A), c-IAP1 RGmt (H588A) and c-IAP1 C7 (del 612-618) proteins were produced as described previously [16] .
Ubiquitination assays and MS analysis
Ubiquitination reactions were performed at 17
• C as described previously [15, 16] and analysed by the ubiquitin-AQUA (absolute quantification) method as described previously [26] , with minor variations. Destained and dehydrated gel pieces from SDS/PAGE were swollen on ice for 20 min in the presence of 20 ng/μl trypsin in 50 mM ammonium bicarbonate/5 % acetonitrile. Gel pieces were pulverized using a Teflon pestle, then digested for 16 h at 37
• C. Ubiquitin-AQUA peptide mixture was prepared in 10 % acetonitrile/5 % methanoic (formic) acid with each peptide at 250 fmol/μl. From this stock, 1500 fmol of ubiquitin-AQUA peptide was added to each sample. Peptides were extracted once using 2 gel vol. of 50 % acetonitrile/5 % methanoic acid, and samples were dried completely. Dry peptides were resuspended in 10 % acetonitrile/5 % methanoic acid/0.01 % H 2 O 2 at least 30 min before analysis. Peptides were loaded on to a 2.1 mm × 150 mm Aquasil (3 μm particle size) C 18 column at 200 μl/min and separated with a multi-stage gradient of buffer B (98 % acetonitrile/0.1 % methanoic acid) in buffer A (2 % acetonitrile/0.1 % methanoic acid) as follows: 5-12.5 % buffer B (0-3 min); 12.5-25 % buffer B (3-18 min); 25-65 % buffer B (18-22 min); 65-85 % buffer B (22-23 min). Multiple reaction monitoring was performed on a QTrap4000 (Applied Biosystems) mass spectrometer with dwell times of 90-220 ms per transition in a segmented run with four to fourteen multiple reaction monitoring transitions per segment. The area of each analyte and internal standard peak was used to determine the abundance of each peptide in the sample. Total ubiquitin abundance was determined as the average of values quantified from the Lys 48 , Lys 63 and Lys 11 loci.
SPR (surface plasmon resonance) measurements
SPR experiments were performed on a Biacore 3000 SPR machine using PBS with 0.005 % Tween 20 and 0.01 % sodium azide as a running buffer. Ubiquitin chains were immobilized directly on to CM5 chips using standard amine coupling chemistry. Measurements of ubiquitin-UBA domain interactions by SPR used a chip with approx. 1500, 7500 and 5000 RU (resonance units) of mono-ubiquitin, Lys 48 -or Lys 63 -linked polyubiquitin respectively, with the c-IAP1 UBA domain injected in a series of concentrations from 100 nM to 100 μM, and other constructs injected over the concentration range 500 nM-25 μM. Data were analysed using BiaEvaluation (GE Healthcare) and Scrubber 2 (BioLogic Software). Binding to mono-ubiquitin generally reached saturation rapidly and was ideal for performing equilibrium binding analysis. Binding kinetics of the UBA domain constructs to both Lys 48 -and Lys 63 -linked polyubiquitin chains could be fitted using a 1:1 binding model with a drifting baseline.
ITC (isothermal titration calorimetry) and CD
ITC experiments were performed on a Microcal VP-ITC calorimeter. Ubiquitin (945 mM) was titrated into the cell containing the c-IAP1 UBA domain (47 μM) in PBS. A total of 25 sequential 8 μl injections were made at 30
• C, with a stirring speed of 300 rev./min and a dwell time of 300 s. Control experiments in which ubiquitin was titrated into buffer alone revealed no significant enthalpy of dilution. CD spectra were acquired on an Aviv AV-215 spectropolarimeter. Spectra were acquired between 198 and 250 nm at 25
• C, scanning every 1 nm, with a 1 s averaging time, and corrected for the buffer signal. Mean residue molar ellipticity [θ ] was calculated as follows:
where θ obs is the observed ellipticity in millidegrees, MRM is the total molecular mass of the protein divided by the number of amino acid residues, l is the optical pathlength in cm, and c is the final protein concentration in mg/ml.
NMR spectroscopy
1 H-, 13 C-and 15 N-NMR spectra were acquired on a Bruker NMR spectrometer with a 1 H Larmor frequency of 800 MHz. Sample buffers consisted of 20 mM Mes (pH 6), 150 mM NaCl in 90
propanesulfonic acid} as an internal reference. Data were processed using TopSpin (Bruker) and analysed using CcpNmr Analysis (http://www.ccpn.ac.uk/software/ccpnmranalysis/introduction).
RESULTS
Analysis of the primary structural requirements for IAP antagonist-stimulated proteasomal degradation of c-IAP1
To examine the primary structural requirements for IAP antagonist-stimulated proteasomal degradation of c-IAP1, a series of constructs was generated in which the functional region of each domain was mutated or the entire domain deleted (see Supplementary Figure S1 at http://www.BiochemJ.org/bj/417/ bj4170149add.htm). The stability of these constructs was investigated in HEK-293T cells using the IAP antagonist BV6 as a stimulus for degradation [16] . Consistent with previous reports [16] , the wild-type c-IAP1 protein is fully degraded following treatment with BV6 (5 μM for 1 h) ( Figure 1A ). In addition, mutations in the BIR1 domain that prevent c-IAP1 from interacting with TRAF2 (T2bm), or mutations in the peptide-binding groove of the BIR2 domain of c-IAP1 (B2E/A or B2ED/AA), had only minor stabilizing effects on BV6-stimulated degradation of c-IAP1 ( Figure 1A) ; the latter results are consistent with the low affinity of BV6 for the BIR2 domain of c-IAP1 [16] . In contrast, mutations in the peptide/BV6-binding groove of the BIR3 domain of c-IAP1 (B3E/A, B3D/A and B3ED/AA) completely blocked BV6-stimulated degradation ( Figure 1A ), in agreement with previous results [16] . The RING domain mutant (RGmt; H588A) of c-IAP1 also was not degraded following BV6 treatment, confirming the importance of auto-ubiquitination for this degradative process ( Figure 1B) . Similarly, deletion of the seven C-terminal amino acids of c-IAP1 ( C7), comprising a motif that is proposed to be critical for IAP dimerization and E3 ubiquitin ligase activity [27] [28] [29] , resulted in resistance to BV6-stimulated degradation ( Figure 1B ). The inability of c-IAP1 RGmt and C7 constructs to mediate auto-ubiquitination was confirmed in a reconstituted ubiquitination assay (see Supplementary Fig ure S2 at http://www.BiochemJ.org/bj/417/bj4170149add.htm).
The effects of mutations in the region of c-IAP1 between the BIR3 and RING domains were also explored (see Supplementary Figure S1 ). Deletion of the CARD ( CARD) had no significant effect on IAP antagonist-stimulated degradation of c-IAP1 ( Figure 1C ). However, deletion of the region between the BIR3 domain and the CARD ( 358-454) resulted in stabilization of c-IAP1 in BV6-treated cells ( Figure 1C ). Therefore, in addition to the BV6-binding BIR3 domain and the E3 ubiquitin ligase RING domain, the region of c-IAP1 between the BIR3 domain and the CARD appears to modulate the stability of c-IAP1.
IAPs possess UBA domains
A PsiBLAST [30] search of the amino acid chain linking the BIR3 domain and the CARD of c-IAP1 shows a region of strong conservation between c-IAP1, c-IAP2, XIAP (X-linked IAP) and ILP2 (IAP-like protein 2), but absent from ML-IAP (melanoma IAP), NAIP (neuronal apoptosis inhibitory protein), survivin and BRUCE (BIR-containing ubiquitin-conjugating enzyme) (see Supplementary Figure S3 ). Secondary-structure prediction by PsiPRED [31] of this IAP segment shows a distinct core pattern of three α-helices marked by an invariant MGF motif in the turn between α1 and α2 ( Figure 2A ). Fold recognition alignments by MUSTER and HHPred [32, 33] revealed a significant similarity of this region of IAPs to UBA domains, a class of ubiquitinbinding domains with a compact three α-helix fold (Figure 2A ) [34] . Notably, most of the known UBA domains contain a highly conserved MGF/Y (Met-Gly-Phe/Tyr) ubiquitin-binding loop that also marks the predicted IAP UBA domains (Figures 2A and  2B ). Comparative modelling of these latter UBA domains atop conventional UBA templates with MODELLER [35] shows that they parsimoniously adopt a typical three α-helix structure with the MGF loop, forming a surface hydrophobic patch (e.g. c-IAP1 in Figure 2B ). Deletion of the UBA domain ( UBA: residues 384-444) rendered c-IAP1 largely resistant to IAP antagoniststimulated proteasomal degradation (see Supplementary Figure S4 at http://www.BiochemJ.org/bj/417/bj4170149add.htm), thus confirming the results obtained with deletion of the extended region between the BIR3 domain and the CARD.
To investigate the biochemical properties of the c-IAP1 UBA domain, single-and double-domain c-IAP1 constructs [BIR3, UBA, UBA (M402A/F404A), CARD, BIR3-UBA and UBA-CARD] were subcloned into expression vectors, expressed in bacteria and purified to homogeneity. The individual UBA domain appeared to be well folded by CD spectroscopy ( Figure 2C ), and showed reasonable amide resonance dispersion in a 15 N-HSQC (heteronuclear single-quantum coherence) NMR spectrum (see Supplementary Figure S5 at http://www.BiochemJ. org/bj/417/bj4170149add.htm). To verify the importance of the MGF loop for the function of the UBA domain, amino acid residues Met 402 and Phe 404 were mutated to alanine. The c-IAP1 UBA (M402A/F404A) double mutant (MF/AA) had NMR and CD spectra that were similar to those of the wild-type construct, suggesting that these two mutations did not affect the overall protein structure (results not shown).
c-IAP1 UBA domain binds mono-ubiquitin and polyubiquitin chains
Among ubiquitin-binding domains, UBA domains possess some of the highest ubiquitin-binding affinities [34] , with some having selective affinity for polyubiquitin chains and others having selective affinity for single ubiquitin domains [36] . A hydrophobic patch on the UBA domains formed by the conserved MGF/Y sequence [37] frequently interacts with the conserved surface hydrophobic patch on ubiquitin formed by Leu 8 , Ile 44 and Val 70 [36] . Thus we sought to determine the affinity of the c-IAP1 UBA domain for multiple forms of ubiquitin through a combination of biophysical techniques and mutagenesis.
Ubiquitin-UBA domain interactions have been characterized extensively using NMR spectroscopy [38] [39] [40] . Thus NMR methods were used to investigate interactions between ubiquitin and the c-IAP1 UBA domain. Titration of 13 ITC and SPR measurements were used to determine the overall affinity and selectivity of the c-IAP1 UBA domain for different types of ubiquitin ( Figures 3C and 3D and Tables 1 and 2 ). Isothermal titration of ubiquitin into the c-IAP1 UBA domain yielded a K d of 5.8 + − 0.3 μM, suggesting a strong affinity for mono-ubiquitin binding. SPR equilibrium affinity measurements of the c-IAP1 UBA domain binding to immobilized monoubiquitin gave a slightly weaker K d estimate of 56 + − 4 μM. No interaction could be observed between the c-IAP1 UBA MF/AA double mutant and mono-ubiquitin by NMR or SPR, suggesting conservation of the canonical ubiquitin-binding interface on the UBA domain [41] . Two-domain c-IAP1 constructs (BIR3-UBA and UBA-CARD) had slightly higher, but similar, equilibrium affinities for mono-ubiquitin (Table 2) . SPR was also used to look at the overall binding kinetics of different UBA constructs with polyubiquitin chains linked to Lys 48 and Lys 63 (Table 1) , although the overall accuracy was lower than that of the ITC and equilibrium SPR measurements, with the primary source of uncertainty being determination of the on-rate (k a ). As with monoubiquitin, the UBA MF/AA double mutant showed no evidence of binding to either type of polyubiquitin chain by SPR measurements (Table 1 ) or in pull-down assay (see Supplementary Figure (Table 1) . These results suggest that binding of the UBA domain to polyubiquitin is accomplished primarily through binding of one UBA domain to individual ubiquitin domains, with no particular selectivity for polyubiquitin over mono-ubiquitin.
The UBA domain does not affect E3 ubiquitin ligase activity of c-IAP1
Ubiquitin ligase activity is critical for most of the signalling activities of c-IAP1 and c-IAP2 [6, 12] . To assess the importance of ubiquitin binding for the E3 ubiquitin ligase activity of c-IAP1, recombinant full-length wild-type c-IAP1 and c-IAP1 MF/AA mutant were incubated in a reconstituted ubiquitination assay for 10 or 35 min. The forms of ubiquitin conjugated to c-IAP1 during auto-ubiquitination reactions were analysed using the ubiquitin-AQUA method [26] . Four gel regions from each sample were excised from the Coomassie Blue-stained SDS/PAGE gel, beginning immediately above the unmodified c-IAP1 bands ( Figures 4A and  4B ). Region D contained the first two visible ubiquitin-c-IAP1 bands, and region B contained the majority of multi-and polyubiquitinated c-IAP1 observed by Western blot against ubiquitin ( Figures 4A and 4B) . Regardless of the gel region, the composition of the ubiquitin linkages generated was very similar between the wild-type and MF/AA mutant versions of c-IAP1, with Lys 11 being the most abundant linkage generated (Figures 4C-4F ). Similar linkage profiles have been reported for other Ubc4/UbcH5a substrates, such as cyclin B1 and Murf1 [26, 42] . The MF/AA mutant of c-IAP1 was somewhat more active than wild-type in generating high-molecular-mass ubiquitinated species in the longer-running reactions (Figures 4C-4E ). Although minimal differences were observed after 10 min, comparison of total ubiquitin abundance in regions B and C for 35 min reactions showed 9.1 and 6.4 pmol respectively for MF/AA c-IAP1 compared with 5.1 and 4.5 pmol respectively for wild-type c-IAP1 (Figures 4D  and 4E ). As expected, ubiquitin in region D consists primarily of mono-and multi-mono-ubiquitinated forms of c-IAP1 (Figure 4F) . On the basis of the low-molecular-mass smear in the Western blot, accumulation of polyubiquitin in Region D after 35 min is best accounted for not by ubiquitin attached to c-IAP1, but rather by free polyubiquitin chains or ubiquitin-UbcH5a ( Figures 4B  and 4F ). Thus the UBA domain of c-IAP1 does not appear to have significant effect on the E3 ubiquitin ligase activity of c-IAP1.
Importance of the UBA domains for c-IAP1-and c-IAP2-mediated signalling
To investigate whether the UBA domain of c-IAP2 is required for its recruitment to the TNFR1 signalling complex, HT1080 cells were transfected with constructs expressing vector, wild-type Figure 5A ). The importance of the UBA domain for binding to TRAF2 and Smac, two established binding partners for c-IAPs, was also tested. Mutations in the TRAF2-binding region of the BIR1 domain of c-IAP2 [24] abrogated interaction with TRAF2, whereas deletion or mutation in the UBA domain of c-IAP2 had no effect on binding (see Supplementary Figure S8A at http://www.BiochemJ.org/bj/417/bj4170149add.htm). In an Table 2 Equilibrium binding measurements to mono-ubiquitin
analogous fashion, mutation of a residue critical for interaction with Smac [43] (Asp 306 to alanine) prevented binding to Smac, whereas deletion or mutation in the UBA domain of c-IAP2 had no effect (see Supplementary Figure S8B ). Similar results were obtained for c-IAP1 UBA domain mutants (results not shown). Thus the UBA domain is not involved in TNFR1 protein complex assembly and is not necessary for association of c-IAP1 and c-IAP2 with TRAF2 or Smac.
Recent studies identified c-IAP1 and c-IAP2 as ubiquitin ligases responsible for the ubiquitination and proteasomal degradation of NIK [16] . MF/AA mutants of c-IAP1 and c-IAP2 were therefore examined for their ability to stimulate proteasomal degradation of NIK and found to be equally potent as their wild-type counterparts ( Figure 5B ). Since NIK degradation relies on the E3 ubiquitin ligase activity of the c-IAPs, these results are not surprising in the light of the findings presented in Figure 4 that mutations in the UBA domain do not overtly affect the ubiquitin ligase activity of c-IAP1.
c-IAP2 undergoes a genetic translocation t(11;18)(q21;q21) that fuses its BIR domains with paracaspase/MALT1 [44, 45] . The c-IAP2-MALT1 fusion protein (case2) constitutively activates the NF-κB pathway, a potentially seminal activity for development of inflammation-associated tumours [46, 47] . To investigate whether mutations in the UBA domain affect NF-κB activation by case2, wild-type and MF/AA mutant case2 were transfected in HEK-293T cells along with the luciferase reporter plasmid (see Supplementary Figure S9A at http://www.BiochemJ.org/ bj/417/bj4170149add.htm). Wild-type and MF/AA mutant case2 stimulated NF-κB activation to comparable extents, whereas deletion of the BIR1 domain severely blunted potency, in agreement with previous results [24, 48] (see Supplementary Figure S7A ). c-IAP2-MALT1 fusion protein is postulated to mediate NF-κB activation by ubiquitinating NEMO (NF-κB essential modulator) [48] . Overexpression of wild-type or MF/AA mutant case2 resulted in similar enhancement of NEMO ubiquitination (see Supplementary Figure S9B ). Therefore the ubiquitin-binding activity of the UBA domain of c-IAP2-MALT1 fusion protein does not appear to be critical for the activation of NF-κB or for NEMO ubiquitination.
To determine the relevance of ubiquitin binding for the anti-apoptotic activity of the c-IAPs, wild-type and MF/AA mutant c-IAP1 and c-IAP2 were transiently expressed in KMS18 multiple myeloma cells. These cells have a genetic ablation in the locus for c-IAPs [49, 50] and thus allowed us to examine their anti-apoptotic role in the absence of endogenous c-IAPs. Expression of wild-type c-IAP1 or c-IAP2 efficiently reduced cell death caused by TNFα in the presence of cyclohexamide, while the MF/AA mutants did not provide significant protection against this apoptotic stimulus ( Figure 5C ). Thus mutations in the UBA domain and abrogation of ubiquitin binding diminish the anti-apoptotic activity of c-IAPs without affecting their recruitment to the TNFR1-associated signalling complex.
The UBA domains of c-IAP1 and c-IAP2 facilitate recruitment to the proteasome
Findings that deletion of the UBA domain affects IAP antagoniststimulated proteasomal degradation of c-IAP1 and c-IAP2 (Figure 1 and Supplementary Figure S3 ) prompted us to investigate whether mutations in amino acid residues critical for binding ubiquitin (MF/AA) would have similar effects. To that end, wild-type and MF/AA mutant constructs of c-IAP1 and c-IAP2 were ectopically expressed in several cell lines and their stability following IAP antagonist treatment was investigated. In all cell lines, MF/AA mutants showed significantly decreased degradation compared with wild-type c-IAPs ( Figure 6A ). This difference appeared to be more pronounced in the case of c-IAP2, which is generally more stable than c-IAP1 [16] (Figure 6A) .
Since ubiquitinated proteins destined for degradation are recruited to the proteasome, and the UBA domain mutants of the c-IAPs are not degraded as efficiently as their wild-type counterparts, we explored the recruitment of the UBA mutant proteins to the proteasome [51, 52] . For this purpose, we ectopically expressed c-IAP1 or its MF/AA mutant and investigated their association with the proteasome receptor RPN13 [53, 54] following IAP antagonist treatment in the presence of MG132 to prevent rapid degradation of the wild-type protein ( Figure 6B) . Treatment of cells with IAP antagonist BV6 promoted interaction of c-IAP1 with endogenous RPN13 (Figure 6B ). In both cell lines examined, c-IAP1 association with RPN13 appeared to be more efficient than for the MF/AA mutant ( Figure 6B ). In a similar fashion, we observed much stronger binding to RPN10 with wild-type c-IAP1 compared with its MF/AA mutant (results not shown). Collectively, these results suggest that the UBA domains of c-IAPs play an important role in their stability and recruitment to the proteasome following exposure to IAP antagonists.
DISCUSSION
One of the most prominent features of IAP antagonists is their capacity to promote auto-ubiquitination and subsequent proteasomal degradation of c-IAP1 and c-IAP2. Our search for structural requirements within c-IAP1 that enable this rapid process identified a novel domain in the IAP family of anti-apoptotic proteins. The UBA domain gives IAPs the ability to bind ubiquitin and extends the list of their interaction partners. It also places IAPs in the ever-growing group of proteins whose binding to ubiquitin modulates their activity and their cellular fate [55] [56] [57] . Interestingly, the UBA domain of c-IAP1 binds mono-ubiquitin and Lys 48 -and Lys 63 -linked polyubiquitin chains with comparable affinities. The selectivity of some UBA domains for relatively linear Lys 63 -linked polyubiquitin chains has recently been postulated to be a consequence of strong affinity for mono-ubiquitin [38] [39] [40] . The ability to bind mono-ubiquitin as well as polyubiquitin chains suggests a wide variety of possible interactions that IAPs can engage through ubiquitin binding.
Investigation of various signalling activities for c-IAP1 and c-IAP2 showed that the UBA domain and its ability to bind ubiquitin are largely dispensable for the recruitment of c-IAPs to the TNFR1 signalling complex or for NF-κB activation. We have, however, observed diminished anti-apoptotic activity of c-IAP1 and c-IAP2 UBA domain mutants, suggesting the possibility that the UBA domain enables interaction of c-IAPs with novel binding partners. Future work involving proteomics and possibly screens of siRNA (small interfering RNA) libraries might identify such novel interactors and help to elucidate a mechanism for this observation. Equally tantalizing will be efforts to elucidate the effect of the XIAP UBA domain on caspase inhibition.
IAP antagonist-stimulated auto-ubiquitination of c-IAP1 and c-IAP2 leads to rapid proteasomal degradation of these proteins. This process requires, among other things, binding of IAP antagonists to the BIR3 domains of the c-IAPs, E3 ubiquitin ligase activity that will mediate auto-ubiquitination and efficient recruitment of ubiquitinated proteins to the proteasome machinery. The ability of the UBA domain to modulate this process implies that this domain should be able to alter one (or more) of these steps.
We have shown that the UBA domain does not interfere with Smac binding, indicating that it does not affect binding of Smac mimetics/IAP antagonists to the c-IAPs. The ability of c-IAP1 and c-IAP2 wild-type and MF/AA mutants to promote NIK degradation to similar extents, together with detailed analysis of their E3 ubiquitin ligase activity in vitro, demonstrated that the UBA domains do not have significant roles in the ubiquitin ligase activity of c-IAPs. Nevertheless, MF/AA mutant c-IAPs were more stable following treatment with IAP antagonists than the wild-type proteins. These findings indicated that the mutant proteins were possibly not recruited to the proteasome very efficiently and that the UBA domains of c-IAPs might facilitate efficient degradation. Indeed, upon investigation of this possibility, we found that c-IAP1 with a mutated UBA domain was poorly recruited to the proteasome after exposure to the IAP antagonist BV6. In addition to testing the binding of ubiquitinated c-IAPs to proteasome receptors RPN10 and RPN13, we also examined the binding of ubiquitinated c-IAPs to shuttle receptors PLIC (protein linking IAP with cytoskeleton) 1 and 2 [51, 52] . However, we could not detect their association with c-IAPs, possibly due to the low affinities of existing antibodies. Earlier studies have indicated that UBA domains can affect proteasomal degradation by regulating the access of the proteasome to the substrate [51, [58] [59] [60] . In a similar fashion, the UBA domains of the c-IAPs might allow fine-tuning of this critical process by modulating its timing and substrate-delivery priority. Proteasomal degradation of ubiquitinated c-IAP1 and c-IAP2 is an extremely rapid event, making it difficult to dissect various steps in the process. Nevertheless, our findings suggest that the UBA domains play an integral role in the recruitment of c-IAP1 and c-IAP2 to the proteasomal machinery and provide a foundation for future studies of IAP antagonist-mediated degradation of the c-IAPs. In vitro auto-ubiquitination reactions were performed using indicated constructs for 5 or 35 min, and ubiquitination and protein input levels were determined by Western blotting (W) using anti-ubiquitin and anti-c-IAP1 antibodies. Ub rxn, ubiquitin reactions; WT, wild-type. The corresponding gap in the ML-IAP (melanoma IAP) sequence between the BIR and the RING domains is a non-globular stretch that is not predicted to fold as a UBA domain. BRUCE, BIR-containing ubiquitin-conjugating enzyme; LRR, leucine-rich repeat; UBC E2, E2 ubiquitin-conjugated enzyme. 
